Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01589874
Other study ID # 328/2007
Secondary ID
Status Recruiting
Phase N/A
First received March 6, 2012
Last updated April 30, 2012
Start date January 2008
Est. completion date December 2014

Study information

Verified date April 2012
Source Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Contact Giovanna Fabio, MD, PhD
Phone +390255033563
Email giovanna.fabio@unimi.it
Is FDA regulated No
Health authority Italy: Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena
Study type Observational

Clinical Trial Summary

Anemia of inflammation (AI), a normochromic, normocytic anemia, associated with abnormal iron utilization, erythropoietin hyporesponsiveness, and decreased red blood cells (RBC) survival is a very common problem in hospitalized patients for acute inflammatory diseases and develops within few days from the onset of illness. Deleterious effects of anemia include increased risk of cardiac related morbidity and mortality in critically ill and older patients.

Anemia is mediated by hepcidin, the 25-amino acid polypeptide hormone that is central to iron trafficking.

Several studies have been performed on pathophysiology of AI in patients affected by chronic diseases but few explore iron metabolism in humans with acute inflammation.

The aim is to develop effective new strategies to detect and manage AI in the setting of acutely ill patients, based on the understanding of iron balance underlying this disorder.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date December 2014
Est. primary completion date March 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria (both):

- serum C-reactive protein level > 3mg/dL

- creatinine level < 2mg/dL (clearance > 30%)

Exclusion Criteria:

- any haematological diseases

- cancer under chemotherapy

- AIDS (or HIV+)

- liver cirrhosis

- genetic hemochromatosis

- immunosuppressive therapy

- blood transfusion in the past 30-days

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
Italy Internal Medicine Department - U.O. Medicina Interna 1/A via Francesco Sforza 35 Milan

Sponsors (2)

Lead Sponsor Collaborator
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico University of Milano Bicocca

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary impact of acute inflammatory state on hemoglobin levels Hemoglobin levels, Blood Red Cells markers, C-RP and other routinary inflammatory markers on day 1 and day 6 (or 8), IL-1, IL-4, IL-6, IL-10, alpha-TNF, gamma-IFN, GDF-15, erythropoietin and hepcidin on day 1 and on day 6 (or 8) 6 days - 8 days Yes
Secondary impact of acute inflammatory cytokines on hepcidin-driven iron balance and monocytes role in anemia of acute inflammation serum iron levels, ferritin and transferrin saturation, circulating monocytes and their HAMP mRNA. 6 days - 8 days Yes